AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Elutia Inc
Video analysis: ELUT
All videosNo video analysis for this stock yet. Request one from our team.
News: ELUT
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th
GAITHERSBURG, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer; Dr. Michelle Williams, Chief Scientific Officer; and Matthew Ferguson, Chief Financial Officer, will present and host one-on-one meetings with investors at the H.C.
Jushi (OTCMKTS:JUSHF) vs. Elutia (NASDAQ:ELUT) Head-To-Head Survey
Elutia (NASDAQ: ELUT - Get Free Report) and Jushi (OTCMKTS:JUSHF - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk. Analyst Recommendations This is a breakdown of current ratings
Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference
GAITHERSBURG, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, Matthew Ferguson, Chief Financial Officer, and Dr. Michelle Williams, Chief Scientific Officer, will participate in two upcoming investor conferences.
Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.
ROSWELL, Ga., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cellution Biologics Inc. (“Cellution Biologics” or the “Company”), a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, today announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix (ADM) business from Elutia Inc. (Nasdaq: ELUT).
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch
Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 months Divestiture further concentrates Elutia's attention and resources on the development and commercialization of NXT-41x NXT-41x is an antibiotic-eluting biomatrix designed to address post-operative infection in the $1.5 billion U.S. plastic and reconstructive surgery market NXT-41x clearance expected in the first half of 2027 GAITHERSBURG, Md., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced it completed the sale of its SimpliDerm® human acellular dermal matrix business to Cellution Biologics Inc. for total consideration of up to $11 million.
Elutia Inc. (ELUT) Q2 2026 Earnings Call Transcript
Elutia Inc. (ELUT) Q2 2026 Earnings Call Transcript
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
Funded through launch: secured up to $26 million of capital without an equity offering The unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection risk The demand is strong: 96% of surgeons surveyed are interested in adopting NXT-41x; 92% responded they would champion it at their hospital value analysis committee On track: NXT-41 FDA clearance decision expected in 4Q 2026; NXT-41x FDA clearance decision expected in 1H 2027 GAITHERSBURG, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and announced financial results for the second quarter ended June 30, 2026.
Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market
$10 million funded at closing; second $5 million tranche unlocked upon FDA 510(k) clearance of NXT-41x Preserves shareholder value by funding commercialization of Elutia's next-generation antibiotic-eluting biomatrix without an equity offering NXT-41x targets the 15–20% post-operative infection rates in multiple complex plastic and reconstructive surgical procedures GAITHERSBURG, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced a $15 million growth capital financing agreement with Avenue Capital Group (“Avenue Capital”).
